The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.
Prescriptions for Adderall more than doubled from the start of the COVID-19 pandemic until September 2022, a new report finds. The FDA reports that the drug is currently in a shortage.